Table 1.
Baseline Characteristics of 429 IDUs According to HCV and HIV Serostatus
| HCV+/ HIV- | HCV+/ HIV+ | HCV-/ HIV- | P-Value | |
|---|---|---|---|---|
| N (%) | 175 (40.8) | 223 (52.0) | 31 (7.2) | |
| Sociodemographic and drug use | ||||
| Malegender | 146 (83.4) | 179 (80.3) | 29 (93.5) | 0.167 |
| Age in years | 30 (26-34) | 31 (28-35) | 27 (23-32) | 0.002 |
| Alcohol consumption ≥ 40 g/day | 38 (21.7) | 67 (30.0) | 15 (48.4) | 0.005 |
| Duration of IDU in years | 7.3 (3.9-12.0) | 12.0 (8.0-16.0) | 1.5 (0.5-6.0) | <0.001 |
| Liver enzymes and other variables | ||||
| Aspartate aminotransferase (U/l) | 32.5 (20-56.3) | 38 (27-67) | 17 (12.8-28.8) | <0.001 |
| % AST > 35 U/l | 46 | 54.4 | 13.3 | |
| Alanine aminotransferase (U/l) | 54 (22.8-99) | 44.5 (27.8-73) | 20.5 (12.8-37.3) | <0.001 |
| % ALT > 45 U/l | 57.5 | 48.6 | 13.3 | |
| Gamma glutamyltransferase (U/l) | 32 (18-52.5) | 51 (25-101) | 20 (13.5-33) | <0.001 |
| % GGT >85 (males)/ >50 (females) | 16.8 | 34.3 | 10.3 | |
| Alkaline phosphatase (U/l) | 68.5 (54-81.3) | 70 (58.5-88.3) | 65.5 (57-88.5) | 0.193 |
| Bilirrubin (mg/100ml) | 0.4 (0.3-0.5) | 0.4 (0.3-0.6) | 0.4 (0.3-0.5) | 0.109 |
| Total cholesterol (mg/100ml) | 159 (143-178) | 147 (128-166) | 174.5 (159-201) | <0.001 |
| Body mass index (kg/m2) | 22 (20.7-24.2) | 21.5 (19.3-23.4) | 21.7 (20.4-24.1) | 0.037 |
| HBsAg+ | 7 (4.1) | 18 (9.0) | 1 (3.4) | 0.122 |
| Current use of antiretroviral treatment | --- | 58 (26.0) | --- | |
| Immunological markers | ||||
| CD4+(cel/µl) | 1220 (911.3-1429.5) | 390 (195.5-650) | 1267 (1043-1440) | <0.001 |
| CD8+(cel/µl) | 864 (701-1134.5) | 900 (665.3-1302.8) | 891 (725-1120) | 0.554 |
NOTE. Results are expressed as median (interquartile range) for continuous variables and absolute frequency (% among non-missing observations) for categorical variables. P-values by Kruskal-Wallis test (continuous variables) and χ2-test (categorical variables).